NOTICE OF INTENT TO SOLE SOURCE

The Centers for Disease Control and Prevention (CDC) has a requirement for a VIDAS 3 instrument and integrated ViLink Gateway Computer to be used as a first tier diagnostic assay for detecting antibodies in patient serum that are reactive to Borrelia spirochetes that cause Lyme disease.

The CDC intends to award a sole-source purchas order to BioMerieux, Incorporated in order to satisfy the requirement. The authority for this action is Federal Acquisition Regulation (FAR) Subsection 13.106-1; in particular, only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). Continuity of ongoing research projects require the use of the VIDAS specific assay, in part, to avoid changing current diagnostic protocols.

This notice of intent is not a request for competitive quotations. This is only an opportunity to provide specific and convincing information that the requirement should instead be competed and the respective capabilities of the responder. All such responses received by the closing date / time of this notice will be considered by the government. A determination by the government whether or not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the government.

Bid Protests Not Available